A Phase 1 interventional study of Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.) and Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.) in Allergy, sponsored by Sandoz. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Sandoz · Phase 1, Interventional, and Treatment
To demonstrate the relative bioavailability study of Loratadine 10 mg tablets.
Sandoz is the lead sponsor of 136 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
Drug: Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
Drug: Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
Drug: Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
Bioequivalence based on AUC and Cmax
Time frame: 54 days
No study locations are listed for this record.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sandoz